Evidence map›Paper›PMID 38069550›Full record

ArticleCancer medicine2023

Physical frailty deteriorates after a 5-day dexamethasone course in children with acute lymphoblastic leukemia, results of a national prospective study.

Emma J Verwaaijen, Annelienke M van Hulst, Annelies Hartman, Rob Pieters, Marta Fiocco, Saskia M F Pluijm, Raphaële R L van Litsenburg, Martha A Grootenhuis, Erica L T van den Akker, Marry M van den Heuvel-Eibrink

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Bibliometric analysis of research trends in the relationship between frailty and neoplasms over the past decade.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Emma J VerwaaijenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-1350-3363
Annelienke M van HulstPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Annelies HartmanDepartment of Pediatric Physiotherapy, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Rob PietersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marta FioccoPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Saskia M F PluijmPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Raphaële R L van LitsenburgPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Martha A GrootenhuisPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Erica L T van den AkkerDepartment of Pediatrics, Division Pediatric Endocrinology, Obesity Center CGG, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Princess Máxima Center · NLErasmus MC - Sophia Children’s Hospital · NLLeiden University · NL

Funding

Stichting de Wonderlijke ReisStichting Kinderen Kankervrij 268
6 · The paper itself

Abstract

backgroundDexamethasone is important in the treatment for pediatric acute lymphoblastic leukemia (ALL) but induces muscle atrophy with negative consequences for muscle mass, muscle strength, and functional abilities. The aim of this study was to establish the effect of a dexamethasone course on sarcopenia and physical frailty in children with ALL, and to explore prognostic factors.

methodsPatients with ALL aged 3-18 years were included during maintenance therapy. Patients had a sarcopenia/frailty assessment on the first day of (T1) and on the day after (T2) a 5-day dexamethasone course. Sarcopenia was defined as low muscle strength in combination with low muscle mass. Prefrailty and frailty were defined as having two or ≥three of the following components, respectively: low muscle mass, low muscle strength, fatigue, slow walking speed, and low physical activity. Chi-squared and paired t-tests were used to assess differences between T1 and T2. Logistic regression models were estimated to explore patient- and therapy-related prognostic factors for frailty on T2.

resultsWe included 105 patients, 61% were boys. Median age was 5.3 years (range: 3-18.8). At T1, sarcopenia, prefrailty, and frailty were observed in respectively 2.8%, 23.5%, and 4.2% of patients. At T2, the amount of patients with frailty had increased to 17.7% (p = 0.002), whereas the number of patients with sarcopenia and prefrailty remained similar. Higher ASMM (odds ratio [OR]: 0.49, 95% CI: 0.28-0.83), stronger handgrip strength (OR: 0.41, 95% CI: 0.22-0.77) and more physical activity minutes per day (OR: 0.98, 95% CI: 0.96-0.99) decreased the risk of frailty at T2. Slower walking performance (OR: 2, 95% CI: 1.2-3.39) increased the risk. Fatigue levels at T1 were not associated with frailty at T2.

conclusionPhysical frailty increased strikingly after a 5-days dexamethasone course in children with ALL. Children with poor physical state at start of the dexamethasone course were more likely to be frail after the course.

Indexed as

FrailtyPrecursor Cell Lymphoblastic Leukemia-LymphomaSarcopeniaChildChild, PreschoolDexamethasoneFatigueFemaleGeriatric AssessmentHand StrengthHumansMaleProspective StudiesDexamethasoneacute lymphoblastic leukemiadexamethasonefrailtymuscle wasting

Identifiers

PMID38069550
PMCPMC10757098
OpenAlexW4389509244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.